- Home
- SD vs LRMR Comparison
SD vs LRMR Comparison
Compare SD & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SD | LRMR |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.8M | 455.8M |
| IPO Year | 2006 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SD | LRMR |
|---|---|---|
| Price | $13.16 | $3.84 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $15.00 | ★ $16.50 |
| AVG Volume (30 Days) | 265.7K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 12.43 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.65 | N/A |
| Revenue Next Year | $1.75 | $1,816.14 |
| P/E Ratio | $26.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $2.72 |
| 52 Week High | $18.45 | $6.42 |
Technical Indicators
Market Signals| Indicator | SD | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 37.64 | 51.08 |
| Support Level | N/A | $3.01 |
| Resistance Level | $13.99 | $4.32 |
| Average True Range (ATR) | 0.32 | 0.28 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 0.41 | 30.57 |
Price Performance
Historical ComparisonAbout SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.